02216 BRONCUS-B
- 0.510
- -0.020-3.77%
BRONCUS-B News
堃博醫療-B：年報2023
Kunbo Medical-B (02216) appoints Xu Hong as chairman
Kunbo Medical-B (02216) announced that since April 19, 2024, Zhao Yiwei has resigned as a non-executive director,...
Kunbo Healthcare (02216.HK) Announces 2023 Annual Results
The development of lung disease treatment products continues to lead, and product sales are steadily advancing in Hangzhou, March 28, 2024/PRNewswire/ -- On March 28, 2024, Kunbo Medical (02216.HK), a leader in precise interventional diagnosis and treatment of lung diseases in China, announced its annual results for the year ended December 31, 2023. During the reporting period, the company achieved product sales revenue of US$12.41 million, an increase of 32% over the previous year. Among them, the total sales revenue of products in mainland China was US$8.62 million, up 48% year on year. In 2023, the company will have a firm industrial layout around “navigation-diagnosis-treatment”, and it will expand
BRONCUS-B: (I) ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023; AND (II) PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION
Kunbo Medical-B (02216.HK) will hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Kunbo Medical-B (02216.HK) announced that the company will hold a board meeting on March 28, 2024 to approve the annual results of the company and its subsidiaries for the year ended December 31, 2023.
BRONCUS-B: DATE OF BOARD MEETING
Kunbo Medical-B Announces Zi Zhenjun's Resignation as Non-Executive Director
Kunbo Medical-B (02216) announced that Zi Zhenjun has resigned as a non-executive director due to his intention to invest more time in other personal matters, effective March 1, 2024.
Kunbo Medical-B (02216): Zi Zhenjun resigns as non-executive director
Kunbo Medical-B (02216) announced that Zi Zhenjun has left due to his intention to spend more time on other personal matters...
Kunbo Medical-B [02216] now reports HK$0.79, an increase of 14.49%
As of 09:39, Kunbo Medical-B [02216] reported HK$0.79, up HK$0.1 or 14.49% from yesterday's closing price, with a turnover of HK$1.3 million, today's high of HK$0.79 and the lowest price of HK$0.75. Based on yesterday's closing price, the 10-day average price was HK$0.69 and the 50-day average price was HK$0.74. The current price-earnings ratio was -1.54 times, and the 14-day strength and weakness index was reported at 39.13.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Broncus Arm Terminates License Agreement With NoahTron Intelligence
Broncus Holding (HKG:2216) said subsidiary Broncus Medical and NoahTron Intelligence Medtech (Hangzhou) have agreed to terminate a license agreement that governed the development of surgical robots, e
Broncus Medical, a subsidiary of Kunbo Medical-B, signed a license termination agreement with Nuochuang
Kunbo Medical-B (02216) issued an announcement. On November 24, 2023, Broncus Medical Inc., a subsidiary of the company, was announced. (Broncus Medical) and Nuotron Intelligent Medical Technology (Hangzhou) Co., Ltd. (Nuotron) entered into a termination agreement. Broncus Medical and Nuochuang agreed to a license agreement with an end date of September 7, 2021, effective November 24, 2023. On September 7, 2021, Broncus Medical signed a license agreement with Nuotron, Bronc
Broncus Unit to Purchase Medical Device Maker
Broncus Holding (HKG:2216) subsidiary Broncus Hangzhou purchased the entire stake in Hangzhou Jingliang Science and Technology from Quantum Engineering (Hong Kong), Suzhou Industrial Park Patience Inv
Broncus Has Announced the Acquisition of the Entire Interest in Hangzhou Jingliang
HANGZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Broncus(2216.HK) is pleased to announce that, on November 23 2023 Broncus Hangzhou (a whollyowned subsidiary of Broncus, as Transferee) has entered into
Press Release: Broncus Has Announced the Acquisition of the Entire Interest in Hangzhou Jingliang
Broncus has announced the acquisition of the entire interest in Hangzhou Jingliang PR Newswire HANGZHOU, China, Nov. 23, 2023 HANGZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Broncus(2216.HK) is plea
Kunbo Medical-B plans to acquire 100% of Hangzhou Precision Science and Technology's shares for 5.4 million yuan
Kunbo Medical-B (02216) announced that on November 23, 2023, Kunbo Hangzhou (a wholly-owned subsidiary of the company, as the buyer) signed an equity transfer agreement with the seller (Quantum Engineering, Suzhou Patience, Hangzhou Denuo) to acquire 100% of the shares in the target company (Hangzhou Precision Technology Co., Ltd.) at a total cost of RMB 5.4 million. Target Company is a professional company focusing on the production and processing of medical devices and software/hardware development. It is committed to building an intelligent manufacturing platform for innovative production, focusing on the development of products, materials and processes, and focusing on medical treatment
Kunbo Medical-B (02216.HK) plans to acquire all of Hangzhou Jingliang's interests for 5.4 million yuan
Gelonghui November 23丨Kunbo Medical-B (02216.HK) announced that on November 23, 2023, Kunbo Hangzhou (as the buyer), a wholly-owned subsidiary of the company, signed an equity transfer agreement with the seller (each and collectively known as Quantum Engineering, Suzhou Patience, and Hangzhou Denuo) to acquire 100% of the shares of the target company Hangzhou Precision Science and Technology Co., Ltd. at a total cost of RMB 5.4 million. The target company is a company that focuses on the production and processing of medical devices and software/hardware development, and has the ability to innovate and produce intelligent manufacturing businesses. With the help of our company, we are supporting
Analysis
Price Target
No Data
